DocGo (DCGO) 주식 개요
는 미국과 영국에서 모바일 헬스케어 서비스 회사로 운영되고 있습니다. 자세히 보기
DCGO Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
DocGo Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$0.67 |
| 52주 최고가 | US$2.45 |
| 52주 최저가 | US$0.49 |
| 베타 | 0.98 |
| 1개월 변동 | 18.32% |
| 3개월 변동 | -6.09% |
| 1년 변동 | -71.30% |
| 3년 변동 | -92.00% |
| 5년 변동 | -93.23% |
| IPO 이후 변동 | -93.45% |
최근 뉴스 및 업데이트
DCGO: Transport EBITDA Outlook Will Drive Future Upside Potential
Analysts recently trimmed their DocGo price targets, with cuts such as Stifel's move from $4.00 to $2.50, citing mixed Q4 results, modestly higher 2026 transport guidance, and updated expectations for growth, margins, and P/E assumptions. Analyst Commentary Bullish analysts acknowledge the recent price target cuts but still point to several areas they see as supportive for DocGo's valuation and long term execution story.
DCGO: Transport EBITDA And 2026 Guidance Will Drive Future Upside Potential
Narrative Update Analysts have nudged their price expectations for DocGo lower, trimming aggregate targets by around $0.10 as they factor in mixed Q4 results, modestly higher 2026 transport guidance, and updated views on margins, growth, and future P/E multiples. Analyst Commentary Recent Street commentary on DocGo is mixed, with some analysts focusing on potential value in the transport segment and others reacting to lower price targets and Q4 variability.DCGO: Transport EBITDA Outlook Will Support Future Upside Potential
Narrative Update The analyst price target for DocGo has been reduced from $4.00 to $2.50, as analysts factor in mixed Q4 results while crediting modestly higher 2026 transport guidance and the view that the transport unit alone could potentially support proceeds above the current share price. Analyst Commentary Recent research reflects a more cautious stance on DocGo, with the price target reduced to US$2.50 while still crediting specific strengths in the transport segment.Recent updates
DCGO: Transport EBITDA Outlook Will Drive Future Upside Potential
Analysts recently trimmed their DocGo price targets, with cuts such as Stifel's move from $4.00 to $2.50, citing mixed Q4 results, modestly higher 2026 transport guidance, and updated expectations for growth, margins, and P/E assumptions. Analyst Commentary Bullish analysts acknowledge the recent price target cuts but still point to several areas they see as supportive for DocGo's valuation and long term execution story.DCGO: Transport EBITDA And 2026 Guidance Will Drive Future Upside Potential
Narrative Update Analysts have nudged their price expectations for DocGo lower, trimming aggregate targets by around $0.10 as they factor in mixed Q4 results, modestly higher 2026 transport guidance, and updated views on margins, growth, and future P/E multiples. Analyst Commentary Recent Street commentary on DocGo is mixed, with some analysts focusing on potential value in the transport segment and others reacting to lower price targets and Q4 variability.DCGO: Transport EBITDA Outlook Will Support Future Upside Potential
Narrative Update The analyst price target for DocGo has been reduced from $4.00 to $2.50, as analysts factor in mixed Q4 results while crediting modestly higher 2026 transport guidance and the view that the transport unit alone could potentially support proceeds above the current share price. Analyst Commentary Recent research reflects a more cautious stance on DocGo, with the price target reduced to US$2.50 while still crediting specific strengths in the transport segment.
DCGO: Future Returns Will Rely On Expanding Telehealth Weight Loss Services
Analysts have trimmed their price targets on DocGo to reflect slightly softer revenue growth assumptions, along with somewhat stronger profit margin and future P/E expectations, resulting in only a modest adjustment to their overall valuation view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the $1.00 minimum bid price requirement.DCGO: Buyback Extension And Telehealth Expansion Will Support Future Upside
Analysts have trimmed their price targets on DocGo to $2.50, citing slightly higher discount rate assumptions, a modestly softer profit margin outlook, and a higher future P/E multiple as key drivers of the revised view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the minimum US$1.00 bid price requirement, triggering a 180 day window until July 27, 2026 to regain compliance before potential further action is considered (Delistings).DCGO: Future Returns Will Rely On Expanding Longitudinal Virtual Weight Loss Care
Analysts have slightly reduced their price target on DocGo, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. This adjustment signals a more cautious stance on the company’s risk and earnings profile.DCGO: Buyback Extension And M&A Pipeline Will Support Future Upside
Analysts have trimmed their price target on DocGo to reflect a fair value shift from about $3.08 to roughly $2.50. The change reflects updated assumptions around revenue contraction, slightly higher required returns, modestly better profit margins, and a lower future P/E multiple.DCGO: Future Returns Will Depend On Expanding Longitudinal Care Partnerships
Analysts have made a small upward tweak to their price target on DocGo, reflecting slightly more constructive assumptions around revenue growth and long term profit margins, while keeping the projected P/E and discount rate almost unchanged. What's in the News Robbins Geller Rudman & Dowd LLP announced a proposed US$12.5 million cash settlement in the DocGo securities class action, subject to court approval at a hearing scheduled for March 24, 2026 in the Southern District of New York (Lawsuits & Legal Issues).DCGO: Future Returns Will Depend On Longitudinal Care And Maturing Revenue Mix
Analysts have nudged up their price target on DocGo by a modest amount, citing slightly higher long term profit margin expectations and a marginally richer future earnings multiple. Together, these factors support a small increase in estimated fair value.DCGO: Future Returns Will Depend On New Longitudinal Care Contracts
Analysts have lowered their price target on DocGo from approximately 1.60 dollars to 1.00 dollars, citing a higher required discount rate and a reduced valuation multiple, despite modest improvements in the projected revenue trajectory and profit margins. What's in the News DocGo signaled an active mergers and acquisitions strategy, highlighting its ability to acquire traditional health care assets and layer on its technology and mobile health capabilities to support long-term growth and shareholder value (company commentary) The company provided updated guidance, forecasting 2025 revenue of 315 million to 320 million dollars, including 68 million to 70 million dollars from migrant-related contracts, and 2026 revenue of 280 million to 300 million dollars with no migrant-related revenue (corporate guidance) DocGo recorded a goodwill impairment charge of approximately 8.7 million dollars in the third quarter of 2025, reflecting a write-down of acquired assets (company filing) DocGo announced a new Longitudinal Care Services program with a California-based insurer, targeting 10,000 under-engaged members with combined telehealth and in-home clinical services starting in the fourth quarter (client announcement) The company is expanding its partnership with a national insurer in New Mexico, launching care gap closure and planned primary care services for 10,000 Turquoise Care members through at-home visits and chronic care support (client announcement) Valuation Changes The fair value estimate has fallen significantly from approximately $1.60 to $1.00 per share.Benign Growth For DocGo Inc. (NASDAQ:DCGO) Underpins Its Share Price
Sep 26
DocGo Inc. (NASDAQ:DCGO) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough
May 16Is It Too Late To Consider Buying DocGo Inc. (NASDAQ:DCGO)?
Apr 16We Like The Quality Of DocGo's (NASDAQ:DCGO) Earnings
Mar 06These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
Mar 01Subdued Growth No Barrier To DocGo Inc. (NASDAQ:DCGO) With Shares Advancing 33%
Feb 11
Innovative Health Initiatives Promise Growth Amid Analysts' Concerns Over Future Earnings And Margins
Strategic partnerships with virtual-only providers and operational efficiency improvements indicate a comprehensive approach to expanding health solutions and improving margins.DocGo Inc. (NASDAQ:DCGO) Doing What It Can To Lift Shares
Aug 05At US$3.40, Is DocGo Inc. (NASDAQ:DCGO) Worth Looking At Closely?
Jul 17These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
Jun 11DocGo: Upside Remains Attractive After Share Price Decline
Mar 20Does DocGo (NASDAQ:DCGO) Have A Healthy Balance Sheet?
Feb 13DocGo: Good Performance, Trust Issues
Feb 05Why DocGo Inc. (NASDAQ:DCGO) Could Be Worth Watching
Jan 25Fewer Investors Than Expected Jumping On DocGo Inc. (NASDAQ:DCGO)
Jan 04주주 수익률
| DCGO | US Healthcare | US 시장 | |
|---|---|---|---|
| 7D | -1.9% | 2.6% | 0.9% |
| 1Y | -71.3% | -3.6% | 28.2% |
수익률 대 산업: DCGO은 지난 1년 동안 -3.6%의 수익을 기록한 US Healthcare 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: DCGO은 지난 1년 동안 28.2%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| DCGO volatility | |
|---|---|
| DCGO Average Weekly Movement | 13.0% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: DCGO의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: DCGO의 주간 변동성(13%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2015 | 3,053 | Lee Bienstock | docgo.com |
는 미국과 영국에서 모바일 의료 서비스 회사로 운영되고 있습니다. 이 회사는 모바일 의료 서비스 및 운송 서비스 부문을 통해 운영됩니다. 이 회사는 응급 대응 서비스와 구급차 및 휠체어 운송 서비스와 같은 비응급 운송 서비스로 구성된 운송 서비스를 제공합니다.
DocGo Inc. 기초 지표 요약
| DCGO 기초 통계 | |
|---|---|
| 시가총액 | US$66.60m |
| 순이익 (TTM) | -US$182.40m |
| 매출 (TTM) | US$322.20m |
0.2x
주가매출비율(P/S)-0.4x
주가수익비율(P/E)DCGO는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| DCGO 손익계산서 (TTM) | |
|---|---|
| 매출 | US$322.20m |
| 매출원가 | US$223.44m |
| 총이익 | US$98.76m |
| 기타 비용 | US$281.16m |
| 순이익 | -US$182.40m |
최근 보고된 실적
Dec 31, 2025
다음 실적 발표일
May 11, 2026
| 주당순이익(EPS) | -1.85 |
| 총이익률 | 30.65% |
| 순이익률 | -56.61% |
| 부채/자본 비율 | 0.2% |
DCGO의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/04 13:40 |
| 종가 | 2026/05/01 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
DocGo Inc.는 7명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Sarah James | Barclays |
| David Larsen | BTIG |
| Richard Close | Canaccord Genuity |